1.Contribution of eukaryotic initiation factor-4E inhibition to heparanase expression and activity in human colon adenocarcinoma cell line LS-174T.
Yu-jie YANG ; Ya-li ZHANG ; Zhuo-sheng LAI ; Ji-de WANG ; Bao-ping WU ; Ya-dong WANG
Chinese Journal of Oncology 2003;25(6):542-545
OBJECTIVETo determine whether the eukaryotic initiation factor-4E (eIF-4E) is involved in the cap-dependent translational regulation of heparanase and study the correlation between heparanase expression and metastatic potential of LS-174T cells.
METHODSThe protein and mRNA levels of inhibited eIF-4E were tested by Western blot and RT-PCR. Heparanase activity was defined as the ability to degrade high molecular weight (40-100 000) radiolabeled ((35)S) heparan sulfate (HS) substrate into low molecular weight (5-15 000) HS fragments. The invasive potential of tumor cells in vitro was observed by Matrigel invasion assay system.
RESULTSThe 20-mer antisense oligonucleotide (asODN) against eIF-4E specifically and significantly inhibited eIF-4E expression at both transcriptional and translational levels. The expression and the activity of heparanase were effectively lowered, which further decreased the invasive potential of LS-174T.
CONCLUSIONeIF-4E, probably being involved in translational regulation of heparanase in colon adenocarcinoma cell line LS-174T, can be a particularly interesting target for heparanase regulation, based on of its critical function.
Adenocarcinoma ; enzymology ; pathology ; Cell Line, Tumor ; Colonic Neoplasms ; enzymology ; pathology ; Eukaryotic Initiation Factor-4E ; antagonists & inhibitors ; genetics ; physiology ; Glucuronidase ; metabolism ; Humans ; Neoplasm Invasiveness
2.P70S6K and Elf4E Dual Inhibition Is Essential to Control Bladder Tumor Growth and Progression in Orthotopic Mouse Non-muscle Invasive Bladder Tumor Model.
Byung Hoon CHI ; Soon Ja KIM ; Ho Kyung SEO ; Hye Hyun SEO ; Sang Jin LEE ; Jong Kyou KWON ; Tae Jin LEE ; In Ho CHANG
Journal of Korean Medical Science 2015;30(3):308-316
We investigated how the dual inhibition of the molecular mechanism of the mammalian target of the rapamycin (mTOR) downstreams, P70S6 kinase (P70S6K) and eukaryotic initiation factor 4E (eIF4E), can lead to a suppression of the proliferation and progression of urothelial carcinoma (UC) in an orthotopic mouse non-muscle invasive bladder tumor (NMIBT) model. A KU-7-luc cell intravesically instilled orthotopic mouse NMIBC model was monitored using bioluminescence imaging (BLI) in vivo by interfering with different molecular components using rapamycin and siRNA technology. We then analyzed the effects on molecular activation status, cell growth, proliferation, and progression. A high concentration of rapamycin (10 microM) blocked both P70S6K and elF4E phosphorylation and inhibited cell proliferation in the KU-7-luc cells. It also reduced cell viability and proliferation more than the transfection of siRNA against p70S6K or elF4E. The groups with dual p70S6K and elF4E siRNA, and rapamycin reduced tumor volume and lamina propria invasion more than the groups with p70S6K or elF4E siRNA instillation, although all groups reduced photon density compared to the control. These findings suggest that both the mTOR pathway downstream of eIF4E and p70S6K can be successfully inhibited by high dose rapamycin only, and p70S6K and Elf4E dual inhibition is essential to control bladder tumor growth and progression.
Animals
;
Cell Line
;
Cell Proliferation/drug effects/genetics
;
Cell Survival/drug effects
;
Disease Progression
;
Eukaryotic Initiation Factor-4E/*antagonists & inhibitors/genetics
;
Female
;
Mice
;
Mice, Nude
;
Mucous Membrane/pathology
;
Phosphorylation/drug effects
;
RNA Interference
;
RNA, Small Interfering
;
Ribosomal Protein S6 Kinases, 70-kDa/*antagonists & inhibitors/genetics
;
Signal Transduction/drug effects
;
Sirolimus/*pharmacology
;
TOR Serine-Threonine Kinases/*antagonists & inhibitors/metabolism
;
Urinary Bladder Neoplasms/genetics/*pathology
;
Urothelium/pathology
3.P70S6K and Elf4E Dual Inhibition Is Essential to Control Bladder Tumor Growth and Progression in Orthotopic Mouse Non-muscle Invasive Bladder Tumor Model.
Byung Hoon CHI ; Soon Ja KIM ; Ho Kyung SEO ; Hye Hyun SEO ; Sang Jin LEE ; Jong Kyou KWON ; Tae Jin LEE ; In Ho CHANG
Journal of Korean Medical Science 2015;30(3):308-316
We investigated how the dual inhibition of the molecular mechanism of the mammalian target of the rapamycin (mTOR) downstreams, P70S6 kinase (P70S6K) and eukaryotic initiation factor 4E (eIF4E), can lead to a suppression of the proliferation and progression of urothelial carcinoma (UC) in an orthotopic mouse non-muscle invasive bladder tumor (NMIBT) model. A KU-7-luc cell intravesically instilled orthotopic mouse NMIBC model was monitored using bioluminescence imaging (BLI) in vivo by interfering with different molecular components using rapamycin and siRNA technology. We then analyzed the effects on molecular activation status, cell growth, proliferation, and progression. A high concentration of rapamycin (10 microM) blocked both P70S6K and elF4E phosphorylation and inhibited cell proliferation in the KU-7-luc cells. It also reduced cell viability and proliferation more than the transfection of siRNA against p70S6K or elF4E. The groups with dual p70S6K and elF4E siRNA, and rapamycin reduced tumor volume and lamina propria invasion more than the groups with p70S6K or elF4E siRNA instillation, although all groups reduced photon density compared to the control. These findings suggest that both the mTOR pathway downstream of eIF4E and p70S6K can be successfully inhibited by high dose rapamycin only, and p70S6K and Elf4E dual inhibition is essential to control bladder tumor growth and progression.
Animals
;
Cell Line
;
Cell Proliferation/drug effects/genetics
;
Cell Survival/drug effects
;
Disease Progression
;
Eukaryotic Initiation Factor-4E/*antagonists & inhibitors/genetics
;
Female
;
Mice
;
Mice, Nude
;
Mucous Membrane/pathology
;
Phosphorylation/drug effects
;
RNA Interference
;
RNA, Small Interfering
;
Ribosomal Protein S6 Kinases, 70-kDa/*antagonists & inhibitors/genetics
;
Signal Transduction/drug effects
;
Sirolimus/*pharmacology
;
TOR Serine-Threonine Kinases/*antagonists & inhibitors/metabolism
;
Urinary Bladder Neoplasms/genetics/*pathology
;
Urothelium/pathology